BetterScholar BetterScholar
11
Role
Title
Level Year L/R
🐜 Cell2location maps fine-grained cell types in spatial transcriptomics
20 auth. Vitalii Kleshchevnikov, Artem Shmatko, Emma Dann, Alexander Aivazidis, Hamish W. King, Tong Li, R. Elmentaite, A. Lomakin, Veronika R. Kedlian, Adam Gayoso, ... M. S. Jain, Jun Sung Park, Lauma Ramona, E. Tuck, A. Arutyunyan, R. Vento-Tormo, M. Gerstung, L. James, O. Stegle, O. Bayraktar
9 2022
9
🐜
🦁 Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies.
10 auth. L. James, M. Shamji, S. Walker, Duncan R. Wilson, P. Wachholz, J. Francis, ... M. Jacobson, I. Kimber, S. Till, S. Durham
8 2011
8
🦁
🐜 Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity.
7 auth. J. Francis, L. James, G. Paraskevopoulos, Cheukyee Wong, M. CalderΓ³n, S. Durham, ... S. Till
8 2008
8
🐜
🐜 IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens
13 auth. Alexandra F Santos, L. James, H. Bahnson, M. Shamji, NatΓ‘lia C. Couto‐Francisco, Sabita Islam, S. Houghton, A. Clark, A. Stephens, V. Turcanu, ... S. Durham, H. Gould, G. Lack
7 2015
7
🐜
🐒 Single-cell analysis of human B cell maturation predicts how antibody class switching shapes selection dynamics
7 auth. Hamish W. King, N. Orban, J. Riches, A. Clear, G. Warnes, S. Teichmann, ... L. James
7 2021
7
🐒
🐜 Proinsulin peptide immunotherapy in type 1 diabetes: report of a first‐in‐man Phase I safety study
14 auth. S. Thrower, L. James, Wayne Hall, K. Green, S. Arif, Jennifer S. Allen, C. Van-Krinks, B. Lozanoska-Ochser, L. G. P. D. Marquesini, S. Brown, ... F. Wong, C. Dayan, M. Peakman, M. Peakman
7 2009
7
🐜
🐜 Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures
21 auth. J. Galson, Sebastian Schaetzle, Rachael J. M. Bashford-Rogers, M. Raybould, Aleksandr Kovaltsuk, Gavin Kilpatrick, R. Minter, Donna K Finch, J. Dias, L. James, ... Gavin Thomas, W. Lee, Jason R. Betley, Olivia Cavlan, Alex Leech, C. Deane, J. Seoane, C. Caldas, D. Pennington, P. Pfeffer, J. Osbourn
6 2020
6
🐜
🐬 The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
D. Baker, G. Pryce, L. James, M. Marta, K. Schmierer
6 2020
6
🐬
🐜 A tool kit for rapid cloning and expression of recombinant antibodies
12 auth. T. Dodev, P. Karagiannis, A. Gilbert, D. Josephs, H. Bowen, L. James, ... H. J. Bax, R. Beavil, M. O. Pang, H. Gould, S. Karagiannis, A. Beavil
6 2014
6
🐜
🦁 Potential Mechanisms for IgG4 Inhibition of Immediate Hypersensitivity Reactions
L. James, S. Till
6 2016
6
🦁
🦁 Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy.
9 auth. L. James, H. Bowen, R. Calvert, T. Dodev, M. Shamji, A. Beavil, ... J. McDonnell, S. Durham, H. Gould
6 2012
6
🦁